This article is more than 5 years old. Information may no longer be current.
Amgen, AstraZeneca: Promising results from second phase 3 of brodalumab for psoriasis
Click Here to Manage Email Alerts
Amgen and AstraZeneca announced that Amagine-3, the multi-arm, phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its endpoints when compared with ustekinumab and placebo at week 12.
Brodalumab had positive results when compared with ustekinumab on the primary endpoint of achieving total clearance of skin disease, when measured by the Psoriasis Severity Index (PASI 100), according to a press release by the company.
When compared with placebo, a significantly greater proportion of patients treated with brodalumab achieved at least a 75% improvement from baseline in disease severity at week 12.
More patients achieved significant skin clearance at week 12 compared with placebo.
The results showed that 36.7% of patients in the brodalumab 210 mg group, 27% in brodalumab 140 mg group, and 18.5% of ustekinumab patients achieved total skin clearance.
In addition, 85.1% of patients in the brodalumab 210 mg group, 69.2% of patients in the brodalumab 140 mg group, 69.3% of patients in the ustekinumab group and 6% of patients in the placebo group achieved PASI 75.
Brodalumab is an investigation treatment which binds to the interleukin-17 receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 cytokines to the receptor, according to the company.